From: Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance
 | Power (%) | Double blind | Experimental arm(s) (ITT sample size) | Control arm (ITT sample size) |
---|---|---|---|---|
CNAAB3005 [10] | NA | Yes | ABA (262) | PI-based regimen (265) |
NEFA [11] | 90 | No | (a) NVP BID (155) | EFV QD (156) |
 |  |  | (b) ABA BID (149) |  |
BEST [12] | 90 | No | IDV/RITO BID (162) | IDV TID (161) |
2NN [13] | 80 | No | (a) NVP QD (220) | EFV (400) |
 |  |  | (b) NVP BID (387) |  |
 |  |  | (c) NVP+EFV (209) |  |
903 [14] | 80 | Yes | TNF (299) | Stavudine (301) |
SOLO [15] | 85 | No | FPV/RITO QD (322) | Nelfinavir BID (327) |
FTC-303 [16] | 85 | No | FTC QD (294) | 3TC BID (146) |
EPV20001 [17] | 80 | Yes | 3TC QD (278) | 3TC BID (276) |
ALIZE [18] | 80 | No | FTC-ddI-EFV QD (178) | PI-based regimen BID/TID (177) |
CNA30024 [19] | 85 | Yes | ABA BID (324) | AZT BID(325) |
BMS-2004 [20] | 90 | Yes | Atazanavir (405) | EFV (405) |
ESS40013 [21] | 80 | No | Stop EFV (141) | Continue EFV (141) |
SEAL [22] | 80 | No | 3TC+ABA QD (130) | 3TC+ABA BID (130) |
BMS-045 [23] | NA | No | (a) ATA/RITO QD (120) | LOPI/RITO BID (123) |
 |  |  | (b) ATA/SAQUI (115) |  |
CNA30021 [24] | 90 | Yes | ABA QD (384) | ABA BID (386) |
CONTEXT [25] | NA | No | (a) FPV/RITO QD (105) | LOPI/RITO BID (103) |
 |  |  | (b) FPV/RITO BID (107) |  |
SHAART [26] | 80 | No | ABA BID (68) | NVP BID (66) |
934 [27] | 85 | No | TNF+FTC QD (255) | AZT+3TC BID (259) |